Vitality Watch

Dossier clinicaltrials trial early 26-jun-2026
Small or early-phase human trial or pilot study

Reducing Frailty for Older Cancer Survivors Using Supplements II

Key claim: A two-arm placebo-controlled RCT is testing whether a 12-week EGCG supplement reduces physical frailty versus placebo in pre-frail older cancer survivors.

Abstract

This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.

Why this matters

A two-arm placebo-controlled RCT is testing whether a 12-week EGCG supplement reduces physical frailty versus placebo in pre-frail older cancer survivors.

Source

Link

Briefing card

Reducing Frailty for Older Cancer Survivors Using Supplements II
Stage: trial early · clinicaltrials · 26-jun-2026

A two-arm placebo-controlled RCT is testing whether a 12-week EGCG supplement reduces physical frailty versus placebo in pre-frail older cancer survivors.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: nct:NCT06068543

build build 880 · 2bcef25 · 2026-11-18